The increasing prevalence of autoimmune disorders, inflammatory diseases, and chronic immune-mediated conditions is driving substantial growth in the global interleukin inhibitors industry. Pharmaceutical companies are focusing on the development of advanced biologics and targeted therapies to improve treatment outcomes and reduce disease progression. Rising healthcare expenditure, increasing...